ADAR1: a promising new biomarker for esophageal squamous cell carcinoma?

References

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G. Esophageal cancer: an update. Int J Surg 2010;8(6):417-22
   PubMedGoogle Scholar
• Bass BL. RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem 2002;71:817-46
   PubMed Web of Science ®Google Scholar
• Kuner R, Groom AJ, Bresink I, et al. Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit. Proc Natl Acad Sci U S A 2005;102(16):5826-31
   PubMed Web of Science ®Google Scholar
• Laxminarayana D, O’Rourke KS, Maas S, Olorenshaw I. Altered editing in RNA editing adenosine deaminase ADAR2 gene transcripts of systemic lupus erythematosus T lymphocytes. Immunology 2007;121(3):359-69
   PubMed Web of Science ®Google Scholar
• Orlowski RJ, O’Rourke KS, Olorenshaw I, et al. Altered editing in cyclic nucleotide phosphodiesterase 8A1 gene transcripts of systemic lupus erythematosus T lymphocytes. Immunology 2008;125(3):408-19
   PubMed Web of Science ®Google Scholar
• Peng PL, Zhong X, Tu W, et al. ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia. Neuron 2006;49(5):719-33
   PubMedGoogle Scholar
• Schulte JH, Marschall T, Martin M, et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res 2010;38(17):5919-28
   PubMed Web of Science ®Google Scholar
• Dominissini D, Moshitch-Moshkovitz S, Amariglio N, Rechavi G. Adenosine-to-inosine RNA editing meets cancer. Carcinogenesis 2011;32(11):1569-77
   PubMedGoogle Scholar
• Keegan LP, Leroy A, Sproul D, O’Connell MA. Adenosine deaminases acting on RNA (ADARs): RNA-editing enzymes. Genome Biol 2004;5(2):209
   PubMedGoogle Scholar
• Qin YR, Qiao JJ, Chan TH, et al. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res 2014;74(3):840-51
   PubMed Web of Science ®Google Scholar
• Fritz J, Strehblow A, Taschner A, et al. RNA-regulated interaction of transportin-1 and exportin-5 with the double-stranded RNA-binding domain regulates nucleocytoplasmic shuttling of ADAR1. Mol Cell Biol 2009;29(6):1487-97
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Saito K, Kin T, et al. Drosophila endogenous small RNAs bind to Argonaute 2 in somatic cells. Nature 2008;453(7196):793-7
   PubMed Web of Science ®Google Scholar
• Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14(4):778-809. table of contents
   PubMed Web of Science ®Google Scholar
• Patterson JB, Samuel CE. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol 1995;15(10):5376-88
   PubMed Web of Science ®Google Scholar
• Nemlich Y, Greenberg E, Ortenberg R, et al. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest 2013;123(6):2703-18
   PubMed Web of Science ®Google Scholar
• Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433(7027):769-73
   PubMed Web of Science ®Google Scholar
• Srivastava D. Making or breaking the heart: from lineage determination to morphogenesis. Cell 2006;126(6):1037-48
   PubMed Web of Science ®Google Scholar
• Wang Q, Miyakoda M, Yang W, et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem 2004;279(6):4952-61
   PubMed Web of Science ®Google Scholar
• Galeano F, Tomaselli S, Locatelli F, Gallo A. A-to-I RNA editing: the "ADAR" side of human cancer. Semin cell Dev Biol 2012;23(3):244-50
   PubMed Web of Science ®Google Scholar
• Nishikura K. Editor meets silencer: crosstalk between RNA editing and RNA interference. Nat Rev Mol Cell Biol 2006;7(12):919-31
   Google Scholar
• Keegan LP, Gallo A, O’Connell MA. The many roles of an RNA editor. Nat Rev Genet 2001;2(11):869-78
   PubMed Web of Science ®Google Scholar
• Paz N, Levanon EY, Amariglio N, et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res 2007;17(11):1586-95
   PubMed Web of Science ®Google Scholar
• Shimokawa T, Rahman MF, Tostar U, et al. RNA editing of the GLI1 transcription factor modulates the output of Hedgehog signaling. RNA Biol 2013;10(2):321-33
   PubMed Web of Science ®Google Scholar
• Chen L, Li Y, Lin CH, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med 2013;19(2):209-16
   PubMed Web of Science ®Google Scholar
• Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461(7265):809-13
   PubMed Web of Science ®Google Scholar
• Cho DS, Yang W, Lee JT, et al. Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J Biol Chem 2003;278(19):17093-102
   PubMed Web of Science ®Google Scholar
• Cenci C, Barzotti R, Galeano F, et al. Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J Biol Chem 2008;283(11):7251-60
   PubMed Web of Science ®Google Scholar
• Martinez HD, Jasavala RJ, Hinkson I, et al. RNA editing of androgen receptor gene transcripts in prostate cancer cells. J Biol Chem 2008;283(44):29938-49
   PubMedGoogle Scholar
• XuFeng R, Boyer MJ, Shen H, et al. ADAR1 is required for hematopoietic progenitor cell survival via RNA editing. Proc Natl Acad Sci U S A 2009;106(42):17763-8
   PubMedGoogle Scholar
• Steinman RA, Yang Q, Gasparetto M, et al. Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice. Int J Cancer 2013;132(8):1741-50
   PubMedGoogle Scholar
• Ma CH, Chong JH, Guo Y, et al. Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias. Biochem Biophys Res Commun 2011;406(2):245-51
   PubMedGoogle Scholar
• Chan TH, Lin CH, Qi L, et al. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut 2013;63(5):832-43
   PubMedGoogle Scholar
• Fujita K, Murakami Y, Hayashi S. A macromolecular inhibitor of the antizyme to ornithine decarboxylase. Biochem J 1982;204(3):647-52
   PubMedGoogle Scholar
• Carroll D. A CRISPR approach to gene targeting. Mol Ther 2012;20(9):1658-60
   PubMedGoogle Scholar
• Schirle NT, Goodman RA, Krishnamurthy M, Beal PA. Selective inhibition of ADAR2-catalyzed editing of the serotonin 2c receptor pre-mRNA by a helix-threading peptide. Org Biomol Chem 2010;8(21):4898-904
   PubMedGoogle Scholar
• Mizrahi RA, Schirle NT, Beal PA. Potent and selective inhibition of A-to-I RNA editing with 2’-O-methyl/locked nucleic acid-containing antisense oligoribonucleotides. ACS Chem Biol 2013;8(4):832-9
   PubMedGoogle Scholar